SCHEMBL21753554

SCHEMBL21753554

CCOC(=O)CCN(N)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
MGAM O43451 1/20 0.41
GAA P10253 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 3/20 0.39
TRPA1 O75762 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
POLB P06746 2/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
ALOX15 P16050 1/20 0.37
KMT2A Q03164 3/20 0.37
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
MEN1 O00255 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23584995 0.85 CYP1A2 (0.44) CYP1A2MGAMGAASIMGAM2
SCHEMBL2039269 0.80 CA12 (0.46) CYP1A2MGAMGAASIMGAM2
SCHEMBL7333667 0.80 CYP1A2 (0.45) CYP1A2MGAMGAASIMGAM2
SCHEMBL15787564 0.78 CYP1A2 (0.48) CYP1A2MGAMGAASIMGAM2
SCHEMBL25490861 0.76 CYP1A2 (0.50) CYP1A2MGAMGAASIMGAM2
SCHEMBL11036410 0.76 CYP1A2 (0.41) CYP1A2MGAMGAASIMGAM2
SCHEMBL12361401 0.75 CYP1A2 (0.48) CYP1A2MGAMGAASIMGAM2
SCHEMBL66021 0.74 ALDH1A1 (0.54) CYP1A2MGAMGAASIMGAM2
SCHEMBL4788929 0.74 MEN1 (0.60) CYP1A2MGAMGAASIMGAM2
SCHEMBL22216388 0.74 GAA (0.48) CYP1A2MGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4582418-A1 CRYSTALLINE FORM OF QUINOLINE DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF TransThera Sciences (Nanjing), Inc. (CN) 2025-07-09 EP disclosed
EP-3842425-B1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES NANJING INC (CN) 2024-05-22 EP disclosed
CN-117624128-A Crystal form of quinoline derivative inhibitor and preparation method and application thereof 药捷安康(南京)科技股份有限公司 2024-03-01 CN disclosed
CN-110857293-B Novel quinoline derivative inhibitor 药捷安康(南京)科技股份有限公司 2023-01-10 CN disclosed
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-10 US disclosed
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-10 US disclosed
EP-3842425-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-06-30 EP disclosed
EP-3842425-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-06-30 EP disclosed
CN-110857293-A Novel quinoline derivative inhibitor 南京药捷安康生物科技有限公司 2020-03-03 CN disclosed
WO-2020038460-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR 南京药捷安康生物科技有限公司 2020-02-27 WO disclosed
WO-2020038460-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR 南京药捷安康生物科技有限公司 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR CSF1R, CSF3R, FLT3 CYP1A2 2757/4885MGAM 3430/4885GAA 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.